Edwards Lifesciences

Edwards benefits from multiple reinforcing moats. Intangible assets: strong brands (SAPIEN, RESILIA, INSPIRIS, PASCAL) with extensive regulatory approvals and clinical evidence (for example, EARLY TAVR and CLASP IID) that drive physician preference and hospital confidence.

Efficient scale: TAVR is a global oligopoly with high barriers in R&D, trials, and manufacturing, where Edwards’ installed base and supply chain enable consistent quality and availability. Switching costs: outcomes, physician training, imaging workflows, and inventory protocols make switching costly and risky for centers.

Cost advantages: scale, learning curves, and premium mix support high gross margins. Network effects are limited but growing data and service layers (e.g., Cordella remote monitoring) can increase stickiness.

Risks: patent expirations, EU and U.S. antitrust scrutiny, and competitors’ innovation (e.g., Medtronic Evolut) could narrow advantages over time. Overall, the competitive position appears durable across a 10‑year horizon but not invulnerable.